Zimmermann Wolfram-Hubertus, Eschenhagen Thomas
Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Trends Cardiovasc Med. 2007 May;17(4):134-40. doi: 10.1016/j.tcm.2007.02.007.
The aim of cardiac tissue engineering is twofold: (1) to provide three-dimensional cardiac tissue to restore the function of diseased hearts and (2) to develop improved test beds for target validation and substance screening. Both concepts have been successfully demonstrated by several groups using immature primary heart cells, but these cells are essentially postmitotic, precluding clinical and large-scale in vitro applications. Identification of a renewable cell source is therefore one of the key objectives in the field. Embryonic stem (ES) cells are attractive candidates because they can be propagated in large quantities, have a robust capacity to differentiate into cardiac myocytes, and can be obtained from humans. Classic isolation of ES cells from the inner cell mass is associated with destruction of the respective embryo. Thus, alternative technologies to generate stem cell lines with ES cell properties are inevitably called for. This review discusses the usefulness of ES cells in cardiac tissue engineering and alternative, embryo-sparing technologies to derive ES cells.
(1)提供三维心脏组织以恢复患病心脏的功能;(2)开发改进的试验平台用于靶点验证和物质筛选。几组研究人员已使用未成熟的原代心脏细胞成功证明了这两个概念,但这些细胞基本上已停止有丝分裂,排除了临床和大规模体外应用的可能性。因此,确定可再生细胞来源是该领域的关键目标之一。胚胎干细胞(ES细胞)是有吸引力的候选细胞,因为它们可以大量增殖,具有强大的分化为心肌细胞的能力,并且可以从人类获取。从内细胞团经典分离ES细胞与相应胚胎的破坏有关。因此,不可避免地需要替代技术来生成具有ES细胞特性的干细胞系。本综述讨论了ES细胞在心脏组织工程中的实用性以及替代的、不破坏胚胎的ES细胞衍生技术。